Prognostic Factors Identified in Mucoepidermoid Carcinoma

This article originally appeared here.
Share this content:
Prognostic Factors Identified in Mucoepidermoid Carcinoma
Prognostic Factors Identified in Mucoepidermoid Carcinoma

(HealthDay News) – Diagnosis of low- or intermediate-grade tumors is associated with significantly better overall survival and disease-free survival in patients with mucoepidermoid carcinoma (MEC) of the salivary glands, while advanced disease stage and perineural invasion are the most significant indicators of poor prognosis, according to a study published in the August 15 issue of Cancer.

Catherine H. McHugh, MD, from the University of Texas MD Anderson Cancer Center in Houston, TX, and colleagues retrospectively reviewed clinical data from 125 patients with salivary gland MEC from 1990 to 2007.

The researchers found that, for all patients, the 5-year overall survival was 79.3% and the disease-free survival was 76.5%. Low- and intermediate-grade disease correlated with significantly better overall and disease-free survival than high-grade disease, with no difference noted in survival rates between low- and intermediate-grade disease. Indicators of poor prognosis included pathologic results of positive lymph nodes, extracapsular lymph node spread, and perineural invasion. Advanced disease stage and perineural invasion were found to be the most significant prognostic factors on multivariate analysis.

"High histological grade, advanced stage, perineural invasion, positive surgical margins, and submandibular location all portend for unfavorable outcomes among patients with MEC," the authors write. "These factors should therefore be taken into consideration when establishing the aggressiveness of a treatment strategy."

Abstract
Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs